CFM
HUMA icon

Catalyst Funds Management’s Humacyte HUMA Stock Holding History

Catalyst Funds Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$162K Buy
+207,900
New +$193K 0.01% 599

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
LWM
LJI Wealth Management Indianapolis, Indiana $714M AUM 21.51% 1-Year Est. Return
UAS
United Asset Strategies Garden City, New York $1.41B AUM 27.73% 1-Year Est. Return
EWM
Endowment Wealth Management Appleton, Wisconsin $259M AUM 15.06% 1-Year Est. Return

Catalyst Funds Management's HUMA Position: Q2 2026 in Review

Catalyst Funds Management opened a new position in Humacyte (HUMA) in Q2 2026: 207,900 shares worth $162K. The stake represents 0.01% of the portfolio and ranks #599 among its holdings.

72 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Catalyst Funds Management held 207,900 shares of Humacyte worth $162K as of Q2 2026.
  • Humacyte was a new Catalyst Funds Management position in Q2 2026.
  • Humacyte made up 0.01% of Catalyst Funds Management's portfolio in Q2 2026, its #599 holding.
  • 72 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.